Literature DB >> 15977092

Preemptive oral rofecoxib plus postoperative intraarticular bupivacaine for pain relief after arthroscopic knee surgery.

Beyhan Karamanlioğlu1, Ayşin Alagöl, Fatma Nesrin Turan.   

Abstract

This study was designed to test the hypothesis whether preemptive administration of rofecoxib, a novel selective COX-2 inhibitor, can prolong intraarticular bupivacaine analgesia after arthroscopic knee surgery. Sixty-two patients were randomly assigned to one of the three groups. Group 1 (n=21) was administered oral rofecoxib 50 mg 1 h before surgery plus intraarticular 0.5 % bupivacaine 20 ml postoperatively. Group 2 (n=21) was administered the same dose of bupivacaine. Group 3 (n=20) was administered saline 20 ml intraarticularly after surgery. Pain scores (VAS) were assessed at 30 min, 1, 2, 4, 6, 12 and 24 h postoperatively. Analgesia duration, analgesic (tramadol and tenoxicam) requirements, and adverse effects were recorded postoperatively for 24 h. Pain scores were significantly lower in the Group 1 at all time points (p<0.05, p<0.001) and were significantly lower in the Group 2 at 30 min (p<0.001), 1 and 4 h (p<0.05) compared to the Group 3. Pain scores were significantly lower in the Group 1 compared to the Group 2 during the first 4 h after surgery (p<0.05, p<0.001). Analgesia duration was longer in Group 1 than Group 2 or 3 (743.0 +/- 480.5 min versus 262.4 +/- 292.2 min and 17.0 +/- 12.1 min; p<0.05, p<0.001 respectively), and in Group 2 than Group 3 (p<0.05). Tramadol requirements were significantly less in Group 1 than Group 2 and 3 (4.8 +/- 15.0 mg versus 40.5 +/- 43.6 mg and 67.5 +/- 24.5 mg; p<0.05, p<0.001 respectively), and in Group 2 than Group 3 (p<0.05). There were no significant differences among the groups regarding the tenoxicam requirements and adverse effects. In conclusion, the combination of oral rofecoxib administered preemptively and intraarticular bupivacaine administered postoperatively provided a significant analgesic benefit and decreased the opioid requirements after arthroscopic knee surgery, when compared to bupivacaine alone or saline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977092

Source DB:  PubMed          Journal:  Agri        ISSN: 1300-0012


  6 in total

Review 1.  Single-dose intra-articular bupivacaine after knee arthroscopic surgery: a meta-analysis of randomized placebo-controlled studies.

Authors:  Jie Wei; Hao-bin Yang; Jia-bi Qin; Fan-jing Kong; Tu-bao Yang
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-06-09       Impact factor: 4.342

2.  Preemptive meloxicam achieves a better effect on postoperative pain control and similar tolerance compared with postoperative meloxicam in patients receiving arthroscopic knee surgery.

Authors:  Yanxin Yuan; Dan Cui; Yunhong Zhang
Journal:  Inflammopharmacology       Date:  2019-06-28       Impact factor: 4.473

3.  Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols.

Authors:  Johannes Fleckenstein; Sybille Kramer; Martin Offenbächer; Gabriel Schober; Herbert Plischke; Matthias Siebeck; Thomas Mussack; Rudolf Hatz; Lukas Lehmeyer; Philip M Lang; Bernhard Heindl; Peter Conzen; Dominik Irnich
Journal:  Trials       Date:  2010-05-27       Impact factor: 2.279

Review 4.  Single administration of intra-articular bupivacaine in arthroscopic knee surgery: a systematic review and meta-analysis.

Authors:  Qi-Bin Sun; Shi-Dong Liu; Qin-Jun Meng; Hua-Zheng Qu; Zheng Zhang
Journal:  BMC Musculoskelet Disord       Date:  2015-02-10       Impact factor: 2.362

5.  Comparative Study between Preemptive and Postoperative Intra-Articular Injection of Levobupivacaine and Tramadol for Control of Postoperative Pain.

Authors:  Ayman Anis Metry; Ramy M Wahba; George M Nakhla; Fady A Abdelmalek; Milad Z Ragaei; Neven G Fahmy
Journal:  Anesth Essays Res       Date:  2019 Jan-Mar

6.  Preemptive analgesia with intra-articular pethidine reduces pain after arthroscopic knee surgery.

Authors:  Sayed Jalal Hashemi; Hasanali Soltani; Sayed Morteza Heidari; Mahmoud Rezakohanfekr
Journal:  Adv Biomed Res       Date:  2013-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.